Fulcrum Therapeutics Sees Positive Results from Pociredir in Sickle Cell Disease Trial
Fulcrum Therapeutics announced positive initial results from its Phase 1b trial of pociredir for sickle cell disease. In the 20mg dose cohort, patients saw a significant increase in hemoglobin F (HbF) levels, with an average increase of 9.9% at six weeks. This represents a substantial improvement over baseline levels, which ranged from 5-7%. Additionally, more … Read more